Drug intelligence / Profile preview

EQL-101

Development stage: Preclinical
Lead developer: EQUULUS Therapeutics
Modality: Small Molecules

Overview

EQL-101 is a psychedelic-inspired anti-addiction therapeutic developed by Equulus Therapeutics. It is a non-hallucinogenic, non-cardiotoxic derivative of ibogaine, a naturally occurring substance used to treat substance use disorders. The drug is a small molecule and is being investigated for its potential to treat various substance use disorders by leveraging the therapeutic benefits of ibogaine without its significant hallucinogenic phase and dangerous cardiac side effects. Its precise mechanism of action is currently undefined.

Beyond the preview

Go deeper on EQL-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EQL-101.

Explore the full profile